For individuals living Pfizer with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Tafamidis meglumine represents a genuine change. These innovative therapies stabilize the transthyretin protein, preventing its harmful build-up and alleviating the severity of the illness. Individuals are now